肿瘤细胞治疗研究
FRONTIER PAPERS
The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Mi
EGFR-Targeting IgG1 Antibody Enhances NK Cell-Mediated Tumor Killing in KRAS-Mutant Pancreatic Cancer.
MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells.
Spatially Defined DNA Origami Cell Engagers for T and Natural Killer Cell-Mediated Immune Modulation.
Tumor microbiome-transcriptome crosstalk identifies Prevotella as an immunotherapeutic predictor in NSCLC.
Glucocorticoid Receptor Activation Reprograms NK Cells to Drive AREG-Mediated Immunosuppression: A Pan-Cancer Role for AREG.
CKLF-like MARVEL transmembrane domain-containing superfamily 8 (CMTM8) promotes Notch signalling to maintain CD8(+) T cell- and NK cell-dependent tumo
Bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumour responses.
Chimeric antigen receptor NK cells for breast cancer immunotherapy.
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor.
MEMBER ACCOUNT
登录成功会直接打开下一页。
